Higher Incidence of Clostridium difficile Infection Among Individuals With Inflammatory Bowel Disease

Gastroenterology

Volumn 153, Issue 2, 2017, Pages 430-438.e2

  Singh, Harminder ^a   Nugent, Zoann ^a,b   Yu, B Nancy ^a,c   Lix, Lisa M ^a   Targownik, Laura E ^a   Bernstein, Charles N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b CANCERCARE MANITOBA   (Canada)

^c Manitoba Health   (Canada)

Author keywords

Epidemiology; Health Care Outcomes; IBD; Risk Factors

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; INFLIXIMAB; MERCAPTOPURINE; METRONIDAZOLE; TUMOR NECROSIS FACTOR ANTIBODY; GASTROINTESTINAL AGENT;

ADULT; AGED; AMBULATORY CARE; ARTICLE; CLINICAL OUTCOME; CLOSTRIDIUM DIFFICILE INFECTION; COHORT ANALYSIS; COLON RESECTION; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE DURATION; FEMALE; FOLLOW UP; HOSPITAL MORTALITY; HOSPITALIZATION; HUMAN; INCIDENCE; INFECTION RISK; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; ULCERATIVE COLITIS; CLOSTRIDIUM INFECTIONS; COMPLICATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FACTUAL DATABASE; INFLAMMATORY BOWEL DISEASES; MANITOBA; MICROBIOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTOCLOSTRIDIUM DIFFICILE; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COHORT STUDIES; DATABASES, FACTUAL; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FEMALE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; MANITOBA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK FACTORS;

EID: 85024846380     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.04.044     Document Type: Article

References (37)

1. To, K.B., Napolitano, L.M., Clostridium difficile infection: update on diagnosis, epidemiology, and treatment strategies. Surg Infect (Larchmt) 15 (2014), 490–502.
2. Reveles, K.R., Lee, G.C., Boyd, N.K., et al. The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001−2010. Am J Infect Control 42 (2014), 1028–1032.
3. Le Monnier, A., Zahar, J.R., Barbut, F., Update on Clostridium difficile infections. Med Mal Infect 44 (2014), 354–365.
4. Berg, A.M., Kelly, C.P., Farraye, F.A., Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis 19 (2013), 194–204.
5. Collins, C.E., Ayturk, M.D., Flahive, J.M., et al. Epidemiology and outcomes of community-acquired Clostridium difficile infections in Medicare beneficiaries. J Am Coll Surg 218 (2014), 1141–1147 e1.
6. Murphy, C.R., Avery, T.R., Dubberke, E.R., et al. Frequent hospital readmissions for Clostridium difficile infection and the impact on estimates of hospital-associated C. difficile burden. Infect Control Hosp Epidemiol 33 (2012), 20–28.
7. Goto, M., Ohl, M.E., Schweizer, M.L., et al. Accuracy of administrative code data for the surveillance of healthcare-associated infections: a systematic review and meta-analysis. Clin Infect Dis 58 (2014), 688–696.
8. Singh, H., Nugent, Z., Yu, B.N., et al. Hospital discharge abstracts have limited accuracy in identifying occurrence of Clostridium difficile infections among hospitalized individuals with inflammatory bowel disease: a population-based study. PLoS One, 12, 2017, e0171266.
9. Depestel, D.D., Aronoff, D.M., Epidemiology of Clostridium difficile infection. J Pharm Pract 26 (2013), 464–475.
10. Roos, L.L., Mustard, C.A., Nicol, J.P., et al. Registries and administrative data: organization and accuracy. Med Care 31 (1993), 201–212.
11. Robinson, J.R., Young, T.K., Roos, L.L., et al. Estimating the burden of disease. Comparing administrative data and self-reports. Med Care 35 (1997), 932–947.
12. Kozyrskyj, A.L., Mustard, C.A., Validation of an electronic, population-based prescription database. Ann Pharmacother 32 (1998), 1152–1157.
13. Bernstein, C.N., Blanchard, J.F., Rawsthorne, P., et al. Epidemiology of Crohn's disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol 149 (1999), 916–924.
14. Singh, H., Demers, A.A., Nugent, Z., et al. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 136 (2009), 451–458.
15. Bernstein, C.N., Nugent, Z., Longobardi, T., et al. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am J Gastroenterol 104 (2009), 2774–2778.
16. Bernstein, C.N., Wajda, A., Blanchard, J.F., The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin.Gastroenterol. Hepatol 6 (2008), 41–45.
17. Longobardi, T., Bernstein, C.N., Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol 102 (2007), 1683–1691.
18. Green, C., Elliott, L., Beaudoin, C., et al. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol 164 (2006), 615–623.
19. Alfa, M.J., Swan, B., VanDekerkhove, B., et al. The diagnosis of Clostridium difficile-associated diarrhea: comparison of triage C. difficile panel, EIA for Tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis 43 (2002), 257–263.
20. Walkty, A., Lagace-Wiens, P.R., Manickam, K., et al. Evaluation of an algorithmic approach in comparison with the Illumigene assay for laboratory diagnosis of Clostridium difficile infection. J Clin Microbiol 51 (2013), 1152–1157.
21. Rea, M.C., O'Sullivan, O., Shanahan, F., et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 50 (2012), 867–875.
22. Galdys, A.L., Nelson, J.S., Shutt, K.A., et al. Prevalence and duration of asymptomatic Clostridium difficile carriage among healthy subjects in Pittsburgh, Pennsylvania. J Clin Microbiol 52 (2014), 2406–2409.
23. Lambert, P.J., Dyck, M., Thompson, L.H., et al. Population-based surveillance of Clostridium difficile infection in Manitoba, Canada, by using interim surveillance definitions. Infect Control Hosp Epidemiol 30 (2009), 945–951.
24. McDonald, L.C., Coignard, B., Dubberke, E., et al. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 28 (2007), 140–145.
25. Chateau, D., Metge, C., Prior, H., et al. Learning from the census: the Socio-economic Factor Index (SEFI) and health outcomes in Manitoba. Can J Public Health 103:Suppl 2 (2012), S23–S27.
26. Kim, H.J., Fay, M.P., Yu, B., et al. Comparability of segmented line regression models. Biometrics 60 (2004), 1005–1014.
27. Evans, C.T., Safdar, N., Current trends in the epidemiology and outcomes of Clostridium difficile infection. Clin Infect Dis 60:Suppl 2 (2015), S66–S71.
28. Goodhand, J.R., Alazawi, W., Rampton, D.S., Systematic review: Clostridium difficile and inflammatory bowel disease. Aliment Pharmacol Ther 33 (2011), 428–441.
29. Joshi, N.M., Marks, I.H., Crowson, R., et al. Incidence and outcome of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease in the UK. J Crohns Colitis 11 (2017), 70–76.
30. Dubberke, E.R., Butler, A.M., Nyazee, H.A., et al. The impact of ICD-9-CM code rank order on the estimated prevalence of Clostridium difficile infections. Clin Infect Dis 53 (2011), 20–25.
31. Scheurer, D.B., Hicks, L.S., Cook, E.F., et al. Accuracy of ICD-9 coding for Clostridium difficile infections: a retrospective cohort. Epidemiol Infect 135 (2007), 1010–1013.
32. Fu, N., Wong, T., Clostridium difficile infection in patients with inflammatory bowel disease. Curr Infect Dis Rep, 18, 2016, 19.
33. Rao, K., Higgins, P.D., Epidemiology, diagnosis, and management of Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis 22 (2016), 1744–1754.
34. Yanai, H., Nguyen, G.C., Yun, L., et al. Practice of gastroenterologists in treating flaring inflammatory bowel disease patients with clostridium difficile: antibiotics alone or combined antibiotics/immunomodulators?. Inflamm Bowel Dis 17 (2011), 1540–1546.
35. Zar, F.A., Bakkanagari, S.R., Moorthi, K.M., et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45 (2007), 302–307.
36. Horton, H.A., Dezfoli, S., Berel, D., et al. Antibiotics for treatment of Clostridium difficile Infection in hospitalized patients with inflammatory bowel disease. Antimicrob Agents Chemother 58 (2014), 5054–5059.
37. Ben-Horin, S., Margalit, M., Bossuyt, P., et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 7 (2009), 981–987.